Exelixis, Inc. (EXEL) Reaches $21.41 After 4.00% Up Move; Amrep Has 1 Sentiment

April 21, 2017 - By Peter Erickson

The stock of Exelixis, Inc. (NASDAQ:EXEL) is a huge mover today! About 1.34 million shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 63.87% since September 14, 2016 and is uptrending. It has outperformed by 53.05% the S&P500.The move comes after 8 months positive chart setup for the $6.34 billion company. It was reported on Apr, 21 by Barchart.com. We have $22.27 PT which if reached, will make NASDAQ:EXEL worth $253.60M more.

Amrep Corporation is a holding company. The company has market cap of $56.55 million. The Company, through its subsidiaries, operates through two divisions: real estate activities and fulfillment services. It currently has negative earnings. The Firm conducts its real estate business through AMREP Southwest Inc. and its subsidiaries, with its activities occurring primarily in the City of Rio Rancho and certain adjoining areas of Sandoval County, New Mexico.

Osmium Partners Llc holds 1.87% of its portfolio in AMREP Corporation for 358,271 shares. Robotti Robert owns 715,504 shares or 1.62% of their US portfolio. Moreover, Weber Alan W has 0.64% invested in the company for 141,960 shares. The New York-based Oppenheimer & Close Llc has invested 0.33% in the stock. Arbiter Partners Capital Management Llc, a New York-based fund reported 113,095 shares.

About 23 shares traded. AMREP Corporation (NYSE:AXR) has declined 4.89% since September 14, 2016 and is downtrending. It has underperformed by 15.71% the S&P500.

Analysts await AMREP Corporation (NYSE:AXR) to report earnings on August, 4.

Investors sentiment decreased to 1.04 in 2016 Q4. Its down 1.03, from 2.07 in 2016Q3. It fall, as 21 investors sold Exelixis, Inc. shares while 78 reduced holdings. 40 funds opened positions while 63 raised stakes. 232.36 million shares or 7.60% more from 215.94 million shares in 2016Q3 were reported. First Trust Advsr L P holds 170,750 shares. Hillsdale Inv Inc holds 0.22% or 70,900 shares in its portfolio. Sector Gamma As accumulated 520,091 shares. Airain Limited has invested 0.13% in Exelixis, Inc. (NASDAQ:EXEL). Fred Alger Mngmt accumulated 0% or 13,000 shares. Commerzbank Aktiengesellschaft Fi reported 11,337 shares stake. Principal Finance Grp Inc Inc holds 0% or 155,076 shares in its portfolio. Trexquant Investment Ltd Partnership holds 55,600 shares or 0.13% of its portfolio. Burt Wealth Advsr owns 2,250 shares or 0.03% of their US portfolio. Zacks Inv Mgmt owns 0.03% invested in Exelixis, Inc. (NASDAQ:EXEL) for 71,827 shares. Smith Asset Mngmt Grp Lp accumulated 29,410 shares. Strs Ohio stated it has 34,400 shares or 0% of all its holdings. Commercial Bank Of America De holds 0% or 354,751 shares. Janus Llc, a Colorado-based fund reported 1.99M shares. California Employees Retirement Systems has invested 0.01% in Exelixis, Inc. (NASDAQ:EXEL).

Since November 9, 2016, it had 0 buys, and 26 insider sales for $26.04 million activity. WYSZOMIERSKI JACK L sold $111,086 worth of stock. Schwab Gisela also sold $1.13 million worth of Exelixis, Inc. (NASDAQ:EXEL) on Wednesday, March 15. MORRISSEY MICHAEL had sold 200,000 shares worth $4.54M. 70,000 shares valued at $1.03 million were sold by Lamb Peter on Tuesday, January 3. FELDBAUM CARL B had sold 10,000 shares worth $217,700 on Monday, March 20. WILLSEY LANCE had sold 10,000 shares worth $228,600. Another trade for 100,000 shares valued at $2.30 million was made by Hessekiel Jeffrey on Friday, March 3.

Analysts await Exelixis, Inc. (NASDAQ:EXEL) to report earnings on May, 3. They expect $-0.01 EPS, up 96.30% or $0.26 from last year’s $-0.27 per share. After $0.12 actual EPS reported by Exelixis, Inc. for the previous quarter, Wall Street now forecasts -108.33% negative EPS growth.

Exelixis, Inc. is a biopharmaceutical company. The company has market cap of $6.34 billion. The Firm is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. It currently has negative earnings. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Among 6 analysts covering Exelixis (NASDAQ:EXEL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Exelixis had 8 analyst reports since January 19, 2016 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $15 target in Thursday, September 15 report. As per Tuesday, February 28, the company rating was downgraded by Stifel Nicolaus. The firm has “Buy” rating by Deutsche Bank given on Thursday, November 3. The firm earned “Overweight” rating on Monday, October 10 by Piper Jaffray. The firm has “Buy” rating given on Monday, April 4 by Stifel Nicolaus. The company was upgraded on Tuesday, January 19 by Leerink Swann.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Top News

No posts yet.